Premature Mortality in Type 2 Diabetes Mellitus Associated with Heart Failure and Chronic Kidney Disease: 20 Years of Real-World Data

Introduction: Type 2 diabetes mellitus (T2D) increases the risk of heart failure (HF) and chronic kidney disease (CKD). Nonetheless, evidence of cardiovascular (CV) prognosis is relatively scarce in young T2D patients. Purpose: To estimate the risk of all-cause death, CV death, and non-fatal major C...

Full description

Bibliographic Details
Main Authors: Cristina Gavina, Daniel Seabra Carvalho, Daniel Martinho Dias, Filipa Bernardo, Hugo Martinho, João Couceiro, Carla Santos-Araújo, Ricardo Jorge Dinis-Oliveira, Tiago Taveira-Gomes
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/11/8/2131
_version_ 1797434520126881792
author Cristina Gavina
Daniel Seabra Carvalho
Daniel Martinho Dias
Filipa Bernardo
Hugo Martinho
João Couceiro
Carla Santos-Araújo
Ricardo Jorge Dinis-Oliveira
Tiago Taveira-Gomes
author_facet Cristina Gavina
Daniel Seabra Carvalho
Daniel Martinho Dias
Filipa Bernardo
Hugo Martinho
João Couceiro
Carla Santos-Araújo
Ricardo Jorge Dinis-Oliveira
Tiago Taveira-Gomes
author_sort Cristina Gavina
collection DOAJ
description Introduction: Type 2 diabetes mellitus (T2D) increases the risk of heart failure (HF) and chronic kidney disease (CKD). Nonetheless, evidence of cardiovascular (CV) prognosis is relatively scarce in young T2D patients. Purpose: To estimate the risk of all-cause death, CV death, and non-fatal major CV events (MACEs) in T2D patients younger than 65 years old. Methods: We designed a retrospective cohort study using incident cases of either T2D, HF, or CKD in the population aged 40–65 years, from 1st January 2000 to 31st December 2019. Each individual was followed for up to one year. The primary analysis consisted of survival analysis with Cox proportional hazards to compare one-year risk of all-cause death, CV death, and MACEs between T2D without HF or CKD (T2D), T2D with HF (T2D-HF), and T2D with CKD (T2D-CKD) groups. Results: A total of 14,986 incident adult diabetic patients from the last two decades in our institution were included with an average age at cohort inclusion of 55–58 years old. Glycemic control was similar among groups. The adjusted hazard ratio (HR) of one-year all-cause death was 2.77 (95% CI: 2.26–3.40) for T2D-HF and 3.09 (2.77–3.45) for T2D-CKD compared with the baseline T2D risk. The highest event rate (T2D-CKD) was 0.15 per person-year. The adjusted HR of one-year CV death was 2.75 (95% CI: 2.19–3.46) for T2D-CKD and 2.59 (1.72–3.91) for T2D-HF. The non-fatal MACE risk was significantly increased in T2D-HF or T2D-CKD compared with T2D (2.82 (CI95%: 2.34–3.41) for T2D-CKD vs. 1.90 (CI95%: 1.66–2.17) for T2D-CKD) with a 32% event rate in non-fatal MACEs. Conclusions: Coexistence of HF or CKD is associated with increased premature mortality as well as non-fatal CV events in T2D patients under 65 years old.
first_indexed 2024-03-09T10:33:28Z
format Article
id doaj.art-c5d2e732cd9f4ff8ab7dacfc13dbed20
institution Directory Open Access Journal
issn 2077-0383
language English
last_indexed 2024-03-09T10:33:28Z
publishDate 2022-04-01
publisher MDPI AG
record_format Article
series Journal of Clinical Medicine
spelling doaj.art-c5d2e732cd9f4ff8ab7dacfc13dbed202023-12-01T21:06:37ZengMDPI AGJournal of Clinical Medicine2077-03832022-04-01118213110.3390/jcm11082131Premature Mortality in Type 2 Diabetes Mellitus Associated with Heart Failure and Chronic Kidney Disease: 20 Years of Real-World DataCristina Gavina0Daniel Seabra Carvalho1Daniel Martinho Dias2Filipa Bernardo3Hugo Martinho4João Couceiro5Carla Santos-Araújo6Ricardo Jorge Dinis-Oliveira7Tiago Taveira-Gomes8Cardiology Department, Pedro Hispano Hospital, 4464-513 Matosinhos, PortugalDepartment of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, 4050-313 Porto, PortugalDepartment of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, 4050-313 Porto, PortugalMedical Department, AstraZeneca, 2730-097 Barbarena, PortugalMedical Department, AstraZeneca, 2730-097 Barbarena, PortugalMedical Department, AstraZeneca, 2730-097 Barbarena, PortugalNephrology Department, Pedro Hispano Hospital, 4464-513 Matosinhos, PortugalTOXRUN–Toxicology Research Unit, University Institute of Health Sciences, Advanced Polytechnic and University Cooperative (CESPU), CRL, 4585-116 Gandra, PortugalDepartment of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, 4050-313 Porto, PortugalIntroduction: Type 2 diabetes mellitus (T2D) increases the risk of heart failure (HF) and chronic kidney disease (CKD). Nonetheless, evidence of cardiovascular (CV) prognosis is relatively scarce in young T2D patients. Purpose: To estimate the risk of all-cause death, CV death, and non-fatal major CV events (MACEs) in T2D patients younger than 65 years old. Methods: We designed a retrospective cohort study using incident cases of either T2D, HF, or CKD in the population aged 40–65 years, from 1st January 2000 to 31st December 2019. Each individual was followed for up to one year. The primary analysis consisted of survival analysis with Cox proportional hazards to compare one-year risk of all-cause death, CV death, and MACEs between T2D without HF or CKD (T2D), T2D with HF (T2D-HF), and T2D with CKD (T2D-CKD) groups. Results: A total of 14,986 incident adult diabetic patients from the last two decades in our institution were included with an average age at cohort inclusion of 55–58 years old. Glycemic control was similar among groups. The adjusted hazard ratio (HR) of one-year all-cause death was 2.77 (95% CI: 2.26–3.40) for T2D-HF and 3.09 (2.77–3.45) for T2D-CKD compared with the baseline T2D risk. The highest event rate (T2D-CKD) was 0.15 per person-year. The adjusted HR of one-year CV death was 2.75 (95% CI: 2.19–3.46) for T2D-CKD and 2.59 (1.72–3.91) for T2D-HF. The non-fatal MACE risk was significantly increased in T2D-HF or T2D-CKD compared with T2D (2.82 (CI95%: 2.34–3.41) for T2D-CKD vs. 1.90 (CI95%: 1.66–2.17) for T2D-CKD) with a 32% event rate in non-fatal MACEs. Conclusions: Coexistence of HF or CKD is associated with increased premature mortality as well as non-fatal CV events in T2D patients under 65 years old.https://www.mdpi.com/2077-0383/11/8/2131early mortalitydiabetesreal-world datacomorbidityMACE
spellingShingle Cristina Gavina
Daniel Seabra Carvalho
Daniel Martinho Dias
Filipa Bernardo
Hugo Martinho
João Couceiro
Carla Santos-Araújo
Ricardo Jorge Dinis-Oliveira
Tiago Taveira-Gomes
Premature Mortality in Type 2 Diabetes Mellitus Associated with Heart Failure and Chronic Kidney Disease: 20 Years of Real-World Data
Journal of Clinical Medicine
early mortality
diabetes
real-world data
comorbidity
MACE
title Premature Mortality in Type 2 Diabetes Mellitus Associated with Heart Failure and Chronic Kidney Disease: 20 Years of Real-World Data
title_full Premature Mortality in Type 2 Diabetes Mellitus Associated with Heart Failure and Chronic Kidney Disease: 20 Years of Real-World Data
title_fullStr Premature Mortality in Type 2 Diabetes Mellitus Associated with Heart Failure and Chronic Kidney Disease: 20 Years of Real-World Data
title_full_unstemmed Premature Mortality in Type 2 Diabetes Mellitus Associated with Heart Failure and Chronic Kidney Disease: 20 Years of Real-World Data
title_short Premature Mortality in Type 2 Diabetes Mellitus Associated with Heart Failure and Chronic Kidney Disease: 20 Years of Real-World Data
title_sort premature mortality in type 2 diabetes mellitus associated with heart failure and chronic kidney disease 20 years of real world data
topic early mortality
diabetes
real-world data
comorbidity
MACE
url https://www.mdpi.com/2077-0383/11/8/2131
work_keys_str_mv AT cristinagavina prematuremortalityintype2diabetesmellitusassociatedwithheartfailureandchronickidneydisease20yearsofrealworlddata
AT danielseabracarvalho prematuremortalityintype2diabetesmellitusassociatedwithheartfailureandchronickidneydisease20yearsofrealworlddata
AT danielmartinhodias prematuremortalityintype2diabetesmellitusassociatedwithheartfailureandchronickidneydisease20yearsofrealworlddata
AT filipabernardo prematuremortalityintype2diabetesmellitusassociatedwithheartfailureandchronickidneydisease20yearsofrealworlddata
AT hugomartinho prematuremortalityintype2diabetesmellitusassociatedwithheartfailureandchronickidneydisease20yearsofrealworlddata
AT joaocouceiro prematuremortalityintype2diabetesmellitusassociatedwithheartfailureandchronickidneydisease20yearsofrealworlddata
AT carlasantosaraujo prematuremortalityintype2diabetesmellitusassociatedwithheartfailureandchronickidneydisease20yearsofrealworlddata
AT ricardojorgedinisoliveira prematuremortalityintype2diabetesmellitusassociatedwithheartfailureandchronickidneydisease20yearsofrealworlddata
AT tiagotaveiragomes prematuremortalityintype2diabetesmellitusassociatedwithheartfailureandchronickidneydisease20yearsofrealworlddata